Summary
The Spanish company has developed a novel regenerative therapy based on the pet's stem cells. It is a painless, fast and efficient treatment that uses the regenerative capacity of the cells themselves to create healthy tissue. Commercial agreement with technical assistance, commercial agency agreement and distribution agreement are sought.
Description
The research SME is specialised in animal health care through regenerative therapies with mesenchymal stem cells (MSC). It is one of the most innovative treatments worldwide in veterinary medicine as no drugs are used, do not cause side effects and are painless treatments.
Stem cells are cells that are found in all multicellular organisms and have the ability to divide to generate more stem cells, while also being able to differentiate into specific cells of other tissues. They have a great power of regeneration or repair of damaged tissues, either repopulating the injured area with the appropriate cells and/or secreting trophic factors that help in the recovery process.
The company obtains the MSC from the adipose tissue of the animal itself (autologous treatment). The veterinarian extracts the pet some fat from the subcutaneous tissue and sends the samples to the company. In the laboratories of the Spanish company, the stem cells are isolated and, after about two weeks, when the cells have proliferated in sufficient numbers and have been suitably characterized, they are re-administered to the pet, either in the injured area or intravenously, depending on the pathology to treat.
The company also provides a plan that consists of the cryopreservation of the mesenchymal stem cells from the pet's adipose tissue isolated in the laboratory at temperatures of -195°C, in liquid nitrogen, sometimes taking advantage of some small surgery already scheduled, such as sterilization, usually at a young age, which reduces the possibility that they present some type of pre-existing infection. In addition, in cell therapy, the vitality of these young cells probably makes their use more recommendable than those of older animals.
The company is interested in finding cooperation partners for commercialisation of the therapy plans.